JAMA Network Home
Sign In
Viewpoint

Advancing a US Single-Payer Model for Cell and Gene Therapy

JAMA Internal Medicine 10.1001/jamainternmed.2025.5058

October 20, 2025 at 11:00 AM EDT

Read the full article

This Viewpoint discusses the status of regulatory approval and reimbursement for cell and gene therapies in Europe and the US.

Corresponding Author: Audun Brendbekken, MD, Bergen Centre for Ethics and Priority Setting in Health (BCEPS), Department of Global Public Health and Primary Care, University of Bergen, Årstadveien 21, 5009 Bergen, Norway (Audun.brendbekken@uib.no).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.5058?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102025

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks